Triple Combination Superior in Progressing or Relapsing Multiple Myeloma Post-ASCT

Share this content:

(ChemotherapyAdvisor) –The triple combination bortezomib-thalidomide-dexamethasone was found to be more effective than the dual combination of thalidomide-dexamethasone in patients with multiple myeloma who progressed or relapsed after autologous transplantation, and “may be considered a new standard of care for this subpopulation of patients,” according to a randomized Phase 3 study in the Journal of Clinical Oncology online May 14.

However, the triple combination was associated with a higher incidence of grade 3 neurotoxicity (29% vs. 12%; P=0.001), the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation MMVAR/IFM 2005-04 trial investigators noted.

In this study, 269 patients were randomly assigned to receive bortezomib (1.3mg/m2 IV bolus) or no bortezomib for 1 year, plus thalidomide (200mg/day orally) and dexamethasone (40mg orally once daily on 4 days once every 3 weeks). Bortezomib was administered on days 1, 4, 8, and 11 with a 10-day rest period (day 12 to day 21) for 8 cycles (6 months), and then on days 1, 8, 15, and 22 with a 20-day rest period (day 23 to day 42) for 4 cycles (6 months).

Median time to progression, the primary endpoint, was significantly longer with bortezomib-thalidomide-dexamethasone than thalidomide-dexamethasone (19.5 vs. 13.8 months; HR, 0.59; P=0.001). In addition, the complete response plus near-complete response rate was higher with the triple combination (45% vs. 25%; P=0.001), and median duration of response was longer (17.2 vs. 13.4 months; P=0.03). The 24-month survival rate favored bortezomib-thalidomide-dexamethasone (71% vs. 65%; P=0.093). Rates of grades 3 and 4 infection and thrombocytopenia were higher with the triple combination.

The study authors noted that in light of the higher rates of neurotoxicity, “we suggest a starting dose of 100mg per day thalidomide for the bortezomib-thalidomide-dexamethasone combination.”


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs